以淀粉样蛋白Aβ为靶点治疗阿尔茨海默病的研究进展

摘要/Abstract

摘要： 阿尔茨海默病(Alzheimer's Disease,AD)是一种以进行性认知功能减退及行动和社会适应能力下降为基本特征的神经退行性疾病,目前临床上仍缺乏有效的药物和治疗手段。已有大量研究表明淀粉样蛋白聚集型β-淀粉样蛋白(β-amyloid,Aβ)可能是AD发生的原发性病理因素之一,并提出Aβ是目前AD治疗药物研发中主要的靶点之一。本文综述了以Aβ为靶点治疗AD的最新研究概况,旨在为AD的新药研发提供一些参考。

关键词: 淀粉样蛋白, 阿尔茨海默病, 研究进展

Abstract: Alzheimer's disease (AD) is a neurodegenerative disease,which is clinically characterized by progressive cognitive decline and the decrease of the behavior and social adaptation ability. Because of the complicated pathogenesis of AD, effective anti-AD drug are very limited in clinical therapy. Growing evidence shows that accumulation of Aβ in the brain is the primary cause of AD and proposes that Aβ could be an important target for anti-AD drugs. This article reviews the latest development of drugs targeting Aβ to treat AD.

Key words: Beta-amyloid, Alzheimer's Disease, Development

中图分类号:

R741

任红, 廖红. 以淀粉样蛋白Aβ为靶点治疗阿尔茨海默病的研究进展[J]. 中国临床药理学与治疗学, 2012, 17(10): 1172-1178.

REN Hong, LIAO Hong. Development of drugs targeting beta-amyloid for Alzheimer's disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(10): 1172-1178.

参考文献

[1] Novák M.Neuroimmunology of Alzheimer's disease[J]. Bratisl Lek Listy,1997,98(6):303-314.
[2] 池卫明. 基于β淀粉样蛋白级联学说的阿尔茨海默病创新药物研发[J].医药导报,2010,29(2):191-193.
[3] Bush AI.Drug development based on the metals hypothesis of Alzheimer's disease[J].Alzheimers Dis,2008,15(2):223-240.
[4] Haass C, Selkoe DJ.Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide[J]. Nat Rev Mol Cell Biol,2007,8(2):101-112.
[5] Lublin AL, Gandy S.Amyloid-beta oligomers: possible roles as key neurotoxins inAlzheimer's Disease[J]. Mt Sinai J Med, 2010, 77(1):43-49.
[6] Leissring MA.The AbetaCs of Abeta-cleaving proteases[J].Biol Chem,2008,283(44):29645-29649.
[7] Cole SL, Vassar R.The Alzheimer's disease beta-secretase enzyme, BACE1[J]. Mol Neurodegener,2007,2:22.
[8] Fukumoto H, Cheung BS, Hyman BT, et al.Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease[J]. Arch Neurol, 2002, 59(9):1381-1389.
[9] Pérez A, Morelli L, Cresto JC, et al.Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains[J]. Neurochem Res, 2000, 25(2):247-255.
[10] Duyckaerts C, Bennecib M, Grignon Y, et al.Modeling the relation between neurofibrillary tangles and intellectual status[J]. Neurobiol Aging,1997,18(3):267-273.
[11] Steinhilb ML, Dias-Santagata D, Fulga TA, et al.Tau phosphorylation sites work in concert to promote neurotoxicity in vivo[J]. Mol Biol Cell,2007,18(12):5060-5068.
[12] Rapoport M, Dawson HN, Binder LI, et al.Tau is essential to beta-amyloid-induced neurotoxicity[J]. Proc Natl Acad Sci USA,2002,99(9):6364-6369.
[13] Cotman CW, Poon WW, Rissman RA, et al.The role of caspase cleavage of tau in Alzheimer disease neuropathology[J].Neuropathol Exp Neurol,2005,64(2):104-112.
[14] Roberds SL, Anderson J, Basi G, et al.BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics[J]. Hum Mol Genet, 2001, 10(12):1317-1324.
[15] Fukumoto H, Takahashi H, Tarui N, et al.A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease[J]. Neurosci, 2010, 30(33):11157-11166.
[16] Stanton MG, Stauffer SR, Gregro AR, et al.Discovery of isonicotinamide derived beta-secretase inhibitors: in vivo reduction of beta-amyloid[J]. Med Chem, 2007,50(15):3431-3433.
[17] Ghosh AK, Gemma S, Tang J. beta-Secretase as a therapeutic target for Alzheimer's disease[J]. Neurotherapeutics, 2008, 5(3):399-408.
[18] Zhu Z, Li C, Wang X, et al.2,2',4'-trihydroxychalcone from Glycyrrhiza glabra as a new specificBACE1 inhibitor efficiently ameliorates memory impairment in mice[J].Neurochem, 2010, 114(2):374-385.
[19] Chang WP, Huang X, Downs D, et al.Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice[J]. FASEB J, 2011, 25(2):775-784.
[20] Watson GS, Cholerton BA, Reger MA, et al.Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study[J]. Am J Geriatr Psychiatry,2005,13(11):950-958.
[21] Sastre M, Dewachter I, Rossner S, et al.Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma[J]. Proc Natl Acad SciUS A,2006,103(2):443-448.
[22] Miller BW, Willett KC, Desilets AR.Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease[J]. Ann Pharmacother,2011,45(11):1416-1424.
[23] Yan R, Bienkowski MJ, Shuck ME, et al.Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity[J]. Nature, 1999, 402(6761):533-537.
[24] Lewis HD, Perez Revuelta BI, Nadin A, et al.Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages[J]. Biochemistry, 2003, 42(24):7580-7586.
[25] Li T, Huang Y, Jin S, et al.gamma-Secretase modulators do not induce Abeta-rebound and accumulation of beta-C-terminal fragment[J]. Neurochem, 2012, 121(2):277-286.
[26] Fleisher AS, Raman R, Siemers ER, et al.Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease[J]. Arch Neurol, 2008, 65(8):1031-1038.
[27] Rafii MS.The pulse of drug development for Alzheimer's disease[J]. Rev Recent Clin Trials, 2010, 5(1):57-62.
[28] Eriksen JL, Sagi SA, Smith TE, et al.NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo[J].Clin Invest,2003,112(3):440-449.
[29] Rafii MS, Aisen PS.Recent developments in Alzheimer's disease therapeutics[J]. BMC Med,2009,7:7.
[30] Postina R.A closer look at alpha-secretase[J]. Curr Alzheimer Res, 2008, 5(2):179-186.
[31] Etcheberrigaray R, Tan M, Dewachter I, et al.Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice[J]. Proc Natl Acad Sci USA, 2004, 101(30):11141-11146.
[32] Panza F, Solfrizzi V, Frisardi V, et al.Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein[J]. Aging Clin Exp Res, 2009, 21(6):386-406.
[33] Gilman S, Koller M, Black RS, et al.Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial[J]. Neurology, 2005, 64(9):1553-1562.
[34] Wilcock GK, Black SE, Hendrix SB, et al.Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial[J]. Lancet Neurol, 2008, 7(6):483-493.
[35] Fan LY, Chiu MJ.Pharmacological treatment for Alzheimer's disease: current approaches and future strategies[J]. Acta Neurol Taiwan, 2010, 19(4):228-245.
[36] Kurz A, Perneczky R.Novel insights for the treatment of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry, 2011 ,35(2):373-379.
[37] Aisen PS, Gauthier S, Ferris SH, et al.Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)[J]. Arch Med Sci,2011, 7(1):102-111.
[38] Hawkes CA, Deng LH, Shaw JE, et al.Small molecule beta-amyloid inhibitors that stabilize protofibrillar structures in vitro improve cognition and pathology in a mouse model of Alzheimer's disease[J]. Eur J Neurosci,2010,(2):203-13.
[39] Opazo C, Huang X, Cherny RA, et al.Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2)[J]. J Biol Chem, 2002, 277(43):40302-40308.
[40] Ritchie CW, Bush AI, Mackinnon A, et al.Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial[J]. Arch Neurol, 2003, 60(12):1685-1691.
[41] McLaurin J, Golomb R, Jurewicz A, et al. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity[J]. J Biol Chem, 2000, 275(24):18495-18502.
[42] Bonda DJ, Lee HP, Lee HG, et al.Novel therapeutics for Alzheimer's disease: an update[J]. Curr Opin Drug Discov Devel, 2010,13(2):235-246.
[43] Martin L, Magnaudeix A, Esclaire F, et al.Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A[J]. Brain Res, 2009,1252:66-75.
[44] Hampel H, Ewers M, Bürger K, et al.Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study[J].Clin Psychiatry, 2009 ,70(6):922-31.
[45] Sabbagh MN, Shill HA.Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea[J]. Curr Opin Investig Drugs. 2010,11(1):80-91.
[46] Bachmeier C, Beaulieu-Abdelahad D, Mullan M, et al.Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier[J]. Eur J Pharmacol. 2011,659(2/3):124-129.
[47] 牛芳,周芳,吴晓兰,等. 血脑屏障上ABC转运体与中枢神经系统疾病相关性的研究进展[J].中国临床药理学与治疗学, 2012,17(2):225-233.
[48] Paris D, Quadros A, Humphrey J, et al.Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice[J]. Brain Res,2004,999(1):53-61.